Fusion Antibodies Plc engages in research, development, and manufacturing recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The company is headquartered in Belfast, Northern Ireland and currently employs 31 full-time employees. The company went IPO on 2017-12-18. The principal activity of the Company is the research, development, and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The company is engaged in providing an integrated end-to-end range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The company offers a range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanization using its proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. The company is also developing OptiMAL, a mammalian antibody library and discovery platform yielding fully human antibodies.